These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23040685)

  • 1. Mucinous histology of colon cancer predicts poor outcomes with FOLFOX regimen in metastatic colon cancer.
    Maisano R; Azzarello D; Maisano M; Mafodda A; Bottari M; Egitto G; Nardi M
    J Chemother; 2012 Aug; 24(4):212-6. PubMed ID: 23040685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study.
    Kim SH; Shin SJ; Lee KY; Kim H; Kim TI; Kang DR; Hur H; Min BS; Kim NK; Chung HC; Roh JK; Ahn JB
    Ann Surg Oncol; 2013 Oct; 20(11):3407-13. PubMed ID: 23943026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal origin.
    Sugarbaker PH; Bijelic L; Chang D; Yoo D
    J Surg Oncol; 2010 Nov; 102(6):576-81. PubMed ID: 20737420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy].
    Cai X; Xue P; Song WF; Hu J; Gu HL; Yang HY; Wang LW
    Zhonghua Zhong Liu Za Zhi; 2012 Jan; 34(1):39-43. PubMed ID: 22490854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy.
    An MS; Yoo JH; Kim KH; Bae KB; Choi CS; Hwang JW; Kim JH; Kim BM; Kang MS; Oh MK; Hong KH
    World J Surg Oncol; 2015 Feb; 13():64. PubMed ID: 25889520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy.
    Lee DW; Han SW; Lee HJ; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
    Br J Cancer; 2013 May; 108(10):1978-84. PubMed ID: 23652310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxaliplatin in patients with metastatic colorectal cancer: efficacy and pharmacokinetics parameters.
    Burz C; Berindan-Neagoe I; Balacescu O; Todor N; Pelau D; Floares C; Kacso G; Tanaselia C; Ursu M; Vlase L; Leucuta SE; Cristea V; Irimie A
    J BUON; 2010; 15(2):263-9. PubMed ID: 20658719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.
    Chang MH; Lee IK; Si Y; Lee KS; Woo IS; Byun JH
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):317-23. PubMed ID: 20972872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Peritoneal tumor pathology - case no. 6: major histologic colloid response of colorectal peritoneal carcinomatosis after induction treatment].
    Bibeau F
    Ann Pathol; 2015 Aug; 35(4):347-50. PubMed ID: 26188675
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
    Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations and prognostic implications of Eastern Cooperative Oncology Group performance status and tumoral LINE-1 methylation status in stage III colon cancer patients.
    Chen D; Wen X; Song YS; Rhee YY; Lee TH; Cho NY; Han SW; Kim TY; Kang GH
    Clin Epigenetics; 2016; 8():36. PubMed ID: 27051466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A case report of advanced mucinous adenocarcinoma of the transverse colon with peritoneal dissemination effectively treated by multidisciplinary approach with a focus on FOLFOX4 therapy combined with panitumumab].
    Asano T; Negita M; Uemura T; Takagi D; Hattori M; Kamiya I
    Gan To Kagaku Ryoho; 2012 Jul; 39(7):1147-9. PubMed ID: 22790058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.
    Han SW; Lee HJ; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
    Int J Cancer; 2013 May; 132(9):2209-16. PubMed ID: 23034738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
    Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
    J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-fluorouracil leucovorin and oxaliplatin (FOLFOX) in the treatment of metastatic colon cancer with severe liver dysfunction.
    Fakih MG
    Oncology; 2004; 67(3-4):222-4. PubMed ID: 15557782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy.
    Catalano V; Loupakis F; Graziano F; Torresi U; Bisonni R; Mari D; Fornaro L; Baldelli AM; Giordani P; Rossi D; Alessandroni P; Giustini L; Silva RR; Falcone A; D'Emidio S; Fedeli SL
    Br J Cancer; 2009 Mar; 100(6):881-7. PubMed ID: 19259089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy.
    Lou YT; Chen CW; Fan YC; Chang WC; Lu CY; Wu IC; Hsu WH; Huang CW; Wang JY
    PLoS One; 2014; 10(4):e0123973. PubMed ID: 25919688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients.
    Goldstein D; Mitchell P; Michael M; Beale P; Friedlander M; Zalcberg J; White S; Clarke S
    Br J Cancer; 2005 Mar; 92(5):832-7. PubMed ID: 15756253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4) as salvage chemotherapy in patients with pretreated colorectal cancer.
    Shitara K; Munakata M; Muto O; Kasai M; Okada R; Mitobe S; Sakata Y
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):1079-84. PubMed ID: 17637544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: single-center study in Korea.
    Kim JY; Kim YJ; Lee KW; Lee JS; Kim DW; Kang SB; Lee HS; Jang NY; Kim JS; Kim JH
    Jpn J Clin Oncol; 2013 Feb; 43(2):132-8. PubMed ID: 23204187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.